Research programme - natural killer cell therapeutics - Fate Therapeutics

Drug Profile

Research programme - natural killer cell therapeutics - Fate Therapeutics

Alternative Names: FT500i; FT516i; hnCD16-iNK; iNK Cells; NcHaCD16-NKs

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fate Therapeutics; University of Minnesota
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Aug 2017 Fate Therapeutics intends to file an IND with the US FDA for FT 500i for Cancer in 1Q 2018
  • 15 May 2017 Fate held a pre-IND meeting with the US FDA and UK MHRA for hnCD16-iNK
  • 01 Apr 2017 Interim pharmacodynamics data from a preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top